Generic name · Weight Loss
Orforglipron(or for glip' ron)
Orforglipron is the active ingredient in Orforglipron. FDA-approved in 2026.
FDA Boxed Warning (orforglipron class-effect)
Risk of thyroid C-cell tumors (class effect). Orforglipron is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Brand names of orforglipron
Currently only one brand markets orforglipron in the US.
Orforglipron
Eli Lilly · FDA-approved 2026
First once-daily oral non-peptide GLP-1. Brand-only, launching via LillyDirect at $149/month. No injection, no compounded versions.
Primary sources
Aggregated from the FDA prescribing information и pivotal trials for every brand of orforglipron.